Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Active Ageing and Health

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03858114
Recruitment Status : Completed
First Posted : February 28, 2019
Last Update Posted : November 10, 2020
Sponsor:
Information provided by (Responsible Party):
Mauro Giovanni Carta, University of Cagliari

Brief Summary:

Background: 36% of the Italian population will have more than 65 years in 2050. The European Union has indicated among its priorities to increase research on active aging. Physical activity contrasts disability linked to chronic diseases, has positive effects on the quality of life and on biological rhythms, prevents the decline of motor functions, improves the immune response, and prevents / positively affects metabolic disorders. It also provides valuable support in coping with cognitive decline and memory, and acts on depressive symptomatology.

The literature on active aging is based, to date, on studies with small samples, rarely conducted with a randomized controlled method, whose outcomes often appear contradictory.

The multidisciplinary project the investigators propose is an opportunity to address the issues mentioned above and to acquire further knowledge in the field of active aging.

Objectives: the main objective of the study is to evaluate the effects of mild-to-moderate physical activity in a sample of over-65 years-old persons, on Quality of Life, and on biomechanical parameters (static-dynamic balance, mobility). The secondary objectives are aimed at assessing whether a protocol of mild-to-moderate physical activity can improve:

  • Metabolic functions
  • Cognitive performance
  • Perception of pain
  • Social rhythms and psychological wellbeing
  • Inflammatory state Design: randomized controlled trial (RCT), single-blinded, with follow-up.

Sample: participants will be ≥ 65 years old, of both genders, sedentary, enrolled in two arms through a random assignment (treatment/control) with ratio of 1:1, as following:

  • about 60 subjects who will carry out a light-to-moderate physical activity intervention (experimental group);
  • about 60 subjects in the control group, who will participate in group cultural activities (active comparison group).

Assessment: the assessment will include socio-demographic variables; variables of psychophysical wellbeing; cognitive variables; variables related to physical health; biomechanical variables; assessment of skin integrity; lab tests on blood samples.

Times of evaluations: both groups will be subjected to the measurements of the present study according to the following schedule:

  • T0 (baseline): before the start of the intervention
  • T1: 12 weeks after T0 (at the end of the intervention)
  • T2: after 20 weeks from T0 (follow up 1)
  • T3: 48 weeks after T0 (follow-up 2).

Condition or disease Intervention/treatment Phase
Aging Chronic Disease Cognitive Decline Quality of Life Physical Activity Other: Mild-to-moderate physical activity Other: Cultural group program Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Active Ageing and Health
Actual Study Start Date : February 28, 2019
Actual Primary Completion Date : February 26, 2020
Actual Study Completion Date : November 8, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Mild-to-moderate physical activity
Three sessions/week, for 12 weeks, of mild-to-moderate physical activity, of mixed type (aerobic-anaerobic), supervised by expert and qualified personnel (physical education instructors) and performed in a gym.
Other: Mild-to-moderate physical activity

According to ACSM guidelines, mild-to-moderate Physical Activity (PA) will be established as ≤ 60% of the Heart Rate Reserve (HRR). Baseline HR will be registered for all participants for three days, and the mean data will be utilized. PA intervention will consist of three phases:

  1. warm up (10 minutes), up to 40% of HRR, with slow, dynamic movements and stretching for principal muscular groups;
  2. Active phase (45 minutes), from >40% to 60% HRR, with static and dynamic exercises for postural control and spine mobility, and balance exercises, with activation of core muscles;
  3. cool down (10 minutes), < 40% of HRR, with cardiorespiratory cool-down exercises followed by relaxation, and post-stretch exercises to return muscles to a pre-exercises length.

Active Comparator: Cultural group program
Cultural group program with thematic meetings and one visit/week to places of historical and artistic interest in the city of Cagliari, Sardinia, accompanied by expert guides (accredited tour guides).
Other: Cultural group program
A cultural group program with 12-weeks thematic meetings on places of historical and artistic interest in the city of Cagliari, Sardinia, with one visit/week to the same sites. The participants will be accompanied by expert tour guides to museums, monuments, city parks and archeological sites.




Primary Outcome Measures :
  1. Change from baseline Short Form Health Survey 12-items (SF-12) score at 12 weeks. [ Time Frame: Baseline (T0), and change from baseline at twelve (T1) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on Quality of Life, measured by the Short Form Health Survey 12-items (SF-12). SF-12 measures perceived Quality of Life, with higher scores corresponding to a better subjective perception of Quality of Life, and can be aggregated as Physical Component score (ranging from 6 to 18), Mental Component score (ranging from 6 to 25), and summed as Global Component score (ranging from 12 to 43).

  2. Change from baseline Short Form Health Survey 12-items (SF-12) score at 20 weeks. [ Time Frame: Baseline (T0), and change from baseline at twenty (T2) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on Quality of Life, measured by the Short Form Health Survey 12-items (SF-12). SF-12 measures perceived Quality of Life, with higher scores corresponding to a better subjective perception of Quality of Life, and can be aggregated as Physical Component score (ranging from 6 to 18), Mental Component score (ranging from 6 to 25), and summed as Global Component score (ranging from 12 to 43).

  3. Change from baseline Short Form Health Survey 12-items (SF-12) score at 48 weeks. [ Time Frame: Baseline (T0), and change from baseline at forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on Quality of Life, measured by the Short Form Health Survey 12-items (SF-12). SF-12 measures perceived Quality of Life, with higher scores corresponding to a better subjective perception of Quality of Life, and can be aggregated as Physical Component score (ranging from 6 to 18), Mental Component score (ranging from 6 to 25), and summed as Global Component score (ranging from 12 to 43).

  4. Change in gait speed measured using inertial sensor [ Time Frame: Baseline (T0), and change from baseline at twelve (T1), twenty (T2), and forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on mobility, assessed by changes in gait speed measured using a single wearable inertial sensor located in the low back (L4-L5 vertebrae)

  5. Change in functional balance measured using inertial sensor [ Time Frame: Baseline (T0), and change from baseline at twelve (T1), twenty (T2), and forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on functional balance, assessed by changes in time needed to complete a 3m Timed-up-and-go (TUG) test. This will be carried out using a single wearable inertial sensor located in the low back (L4-L5 vertebrae)


Secondary Outcome Measures :
  1. Change in anthropometric measurements: BMI [ Time Frame: Baseline (T0), and change from baseline at twelve (T1), twenty (T2), and forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on BMI (Body Mass Index), measured as the body weight divided by the square of the body height (kg/ m2).

  2. Change in anthropometric measurements: waist circumference [ Time Frame: Baseline (T0), and change from baseline at twelve (T1), twenty (T2), and forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on waist circumference, measured in centimeters.

  3. Change in body composition [ Time Frame: Baseline (T0), and change from baseline at twelve (T1), twenty (T2), and forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on body composition (e.g. lean and fat mass, and total body water), measured by bioimpedentiometry.

  4. Change in cognitive status. [ Time Frame: Baseline (T0), and change from baseline at twelve (T1), twenty (T2), and forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on cognitive functions, assessed by the Addenbrooke's Cognitive Examination Revised (ACE-R), which contains 5 sub-scores, each one representing one cognitive domain: attention/orientation (18 points), memory (26 points), fluency (14 points), language (26 points) and visuospatial (16 points). ACE-R maximum score is 100, composed by the addition of the all domains.

  5. Change in inflammatory status: blood cells count. [ Time Frame: Baseline (T0), and change from baseline at twelve (T1) and twenty (T2) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on inflammatory status, measured by lab analyses (CBC + fl. + Plt), measured by blood cells count (e.g. erythrocytes count, total and differential leucocytes count, platelets count), measured as number of cells/microliter. The normal red blood cells (RBC) range for men is 4.7 to 6.1 million cells/mcL, for women is 4.2 to 5.4 million mcL. The normal white blood cells (WBCs) count ranges 5000-10000/mcL, with normal percentages of WBCs types as following: 55-73% neutrophils, 20-40% lymphocytes, 2-8% monocytes, 1-4% eosinophils, 0.5-1% basophils. The normal platelets count ranges 150000-450000/mcL.

  6. Change in inflammatory status: erythrocyte sedimentation rate. [ Time Frame: Baseline (T0), and change from baseline at twelve (T1) and twenty (T2) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on inflammatory status, measured by erythrocyte sedimentation rate (ESR). The normal range is 0-22 millimeters/hour for men and 0-29 millimeters/hour for women.

  7. Change in inflammatory status: C-reactive proteine. [ Time Frame: Baseline (T0), and change from baseline at twelve (T1) and twenty (T2) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on inflammatory status, measured by C-reactive proteine (CRP). Normal concentrations of CRP varies between 0.8 mg/L to 3.0 mg/L.

  8. Change in metabolic status: basal glycaemia. [ Time Frame: Baseline (T0), and change from baseline at twelve (T1) and twenty (T2) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on metabolic status, measured by basal glycaemia, ranging from 72 to 99 mg/dL.

  9. Change in metabolic status: blood lipids. [ Time Frame: Baseline (T0), and change from baseline at twelve (T1) and twenty (T2) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on metabolic status, measured as blood lipids concentration (mg/dL) for Total cholesterol (limit value: 199 mg/dL) , HDL cholesterol (normal value men: 41-59 mg/dL; normal value women: 51-60 mg/dL), Triglycerides (normal value: 150-199 mg/dL).

  10. Change in psychological wellbeing [ Time Frame: Baseline (T0), and change from baseline at twelve (T1), twenty (T2), and forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on depressive/anxiety symptoms, assessed by the Patient Health Questionnaire-9 items (PHQ-9) questionnaire. The PHQ-9 ranges from 0 (no psychopathological symptoms, better score) to 27 (worse score), with minor depression cut-off for scores ≥5, and major depressive disorder cut-off scores ≥10.

  11. Change in social rhythms [ Time Frame: Baseline (T0), and change from baseline at twelve (T1), twenty (T2), and forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on social rhythms, assessed by the Brief Social Rhythms Scale (BSRS) questionnaire. The BSRS consists of ten items, assessing the general regularity with which interviewed engage in basic daily activities during the workweek and on the weekend, ranging from 1 (very regularly) to 6 (very irregularly), with high mean scores indicating high irregularity. Summary scores are the average across all 10 items.

  12. Change in disability perception [ Time Frame: Baseline (T0), and change from baseline at twelve (T1), twenty (T2), and forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on physical disability perception, measured by the Sickness Impact Profile-Roland (SIP-Roland) scale for disability. The SIP-Roland scale is a 23-items questionnaire with a total score ranging from 0 (better score, no disability) to 23 (worse score).

  13. Change in pain perception [ Time Frame: Baseline (T0), and change from baseline at twelve (T1), twenty (T2), and forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on physical pain perception, measured by the NPRS (Numeric Pain Rating Scale). The NPRS is a visual-analogic scale rating the current pain perception, ranging from 0 (better score, no pain) to 10 (the worst pain imaginable).

  14. Change in wrinkles severity [ Time Frame: Baseline (T0), and change from baseline at twelve (T1), twenty (T2), and forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on wrinkles severity, measured by Visual Wrinkles Scale, assessing the wrinkles grade ranging from 0 (no wrinkles) to 5 (very deep wrinkle, redundant fold) in the following anatomic points: horizontal forehead lines, glabellar frown lines, periorbital lines, preauricular lines, cheek lines, naso-labial folds, radial upper and lower lip lines, corner of the mouth lines, "marionette lines", labiomental crease, horizontal neck folds.

  15. Change in skin integrity [ Time Frame: Baseline (T0), and change from baseline at twelve (T1), twenty (T2), and forty-eight (T3) weeks from baseline. ]
    effect of a light-to-moderate physical activity intervention on skin integrity, measured by videodermoscopy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • sedentary (do not practicing regular physical activity, at least 2 times a week, for at least 6 months).
  • certificate of fitness for non-competitive physical activity issued by a specialist in Sports Medicine.

Exclusion Criteria:

  • BMI (Body Mass Index)>35;
  • severe cardiovascular disease, such as myocardial infarction in the previous 2 years, aorto-coronary bypass, pacemaker or mechanical valvular prosthesis, aortic stenosis, acute pericarditis, acute myocarditis, aneurysms, angina, arrhythmias, moderate or severe aortic and mitral valve failure, arterial pressure at rest: systolic> 200 mmHg, or diastolic> 100 mmHg, pharmacologically non-compensated chronic atrial fibrillation, treatment with oral anticoagulants, thrombophlebitis or pulmonary embolism in the previous 2 years, ongoing moderate/severe anemia (Hb <10 mg / dL);
  • serious problems of autonomous walking, such as fractures of the lower limbs in the previous 2 years, upper limb fractures in the previous 6 months, surgical interventions (non-arthroscopic) in the joints in the previous 2 years, any reason of absolute immobility for more than a week in the previous two months, and for more than two weeks in the previous 6 months, severe osteoporosis, walking problems (eg, use of crutches or stick);
  • severe metabolic disorders, such as insulin-treated diabetes mellitus or with HbA1c > 8, or pharmacologically non-compensated thyreopathies (hyper/hypothyroidism);
  • severe neurological conditions that determine the impossibility to carry out the physical activity protocol, such as stroke cerebri in the previous 2 years, or Parkinson's disease;
  • severe bronchopulmonary disorders, such as severe bronchial asthma, severe chronic obstructive pulmonary disease, or pulmonary emphysema;
  • severe renal disorders and make dialysis;
  • severe glaucoma or retinal detachment in the previous 3 months;
  • malignant neoplasm in progress, or in the previous 2 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03858114


Locations
Layout table for location information
Italy
Centro Obesità, AOU Cagliari
Cagliari, Italy, 09100
Clinica Dermatologica, AOU Cagliari
Cagliari, Italy, 09100
P.O. San Giovanni di Dio, AOU Cagliari
Cagliari, Italy, 09100
Sponsors and Collaborators
University of Cagliari
Investigators
Layout table for investigator information
Principal Investigator: Mauro Giovanni Carta, MD University of Cagliari
Publications of Results:

Layout table for additonal information
Responsible Party: Mauro Giovanni Carta, Professor, University of Cagliari
ClinicalTrials.gov Identifier: NCT03858114    
Other Study ID Numbers: PG/2018/15546
First Posted: February 28, 2019    Key Record Dates
Last Update Posted: November 10, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Disease
Cognitive Dysfunction
Disease Attributes
Pathologic Processes
Cognition Disorders
Neurocognitive Disorders
Mental Disorders